Lincoln Pharmaceuticals Limited — Important, 14-11-2024: Financial Result Updates

Lincoln Pharmaceuticals Ltd. has announced a board meeting on November 14, 2024, where they approved the consolidated financial results for the quarter and half-year ended September 30, 2024.

**Consolidated Financial Highlights:**

- **Total Income:** ₹171.19 crore for Q2 FY25, up 5.40% from ₹162.85 crore in Q2 FY24. For H1 FY25, total income reached ₹328.88 crore, reflecting a 6.78% increase from ₹307.99 crore in H1 FY24.

- **Revenue Growth:** The revenue from operations improved by 5.79% year-on-year, attributed to market expansion and effective demand management.

- **Net Profit:** Came in at ₹26.33 crore for Q2 FY25, marking a 7.55% increase from ₹24.42 crore in Q2 FY24. The half-year saw net profit at ₹50.03 crore, up from ₹46.52 crore YoY.

- **Earnings Per Share (EPS):** Reported at ₹13.15 for the quarter and ₹24.96 for the half-year, indicating a healthy growth trajectory.

**Operational Costs:** The overall expenses were ₹136.41 crore, representing an increase from ₹128.21 crore YoY. Significant factors impacting operational costs included employee benefits and other expenses.

**Balance Sheet and Cash Flow:** The company's total assets increased to ₹779.79 crore, up from ₹700.30 crore as of March 31, 2024. The cash flow from operations for the half-year was robust at ₹42.32 crore, signaling strong operational efficiency.

**Strategic Position and Outlook:** Lincoln aims for a revenue target of ₹750 crore by FY26 through strategic expansion and diversification into new product lines, particularly in women’s healthcare and chronic diseases. They are also focused on maintaining a debt-free status, indicative of robust financial management.

**Investor Insight:** Given the company's consistent revenue growth, solid profitability, and strategic initiatives, it may be prudent for investors to consider this stock as a buy for long-term growth.